Actively Recruiting

Age: 18Years - 75Years
All Genders
NCT06979869

Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma

Led by Xijing Hospital · Updated on 2025-12-16

300

Participants Needed

9

Research Sites

248 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The primary objective is to determine whether pretreatment-to-posttreatment changes in circulating multigene methylation levels correlate with objective response rates (ORR) assessed by contrast-enhanced CT/MRI and levels of serum tumor markers. Secondary endpoints include: (a) time-dependent association between methylation fluctuation patterns and progression-free survival (PFS), (b) comparative diagnostic accuracy of methylation indices versus conventional biomarkers, and (c) feasibility of using methylation thresholds to guide adaptive therapy modification.

CONDITIONS

Official Title

Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age at initial diagnosis: 18-75 years (inclusive)
  • Histologically proven esophageal carcinoma with complete medical records
  • Definitive pathological diagnosis report available
  • TNM staging according to AJCC 8th edition criteria
  • No prior malignancies at other anatomical sites except cured non-melanoma skin cancers or carcinoma in situ
  • No distant metastases in liver, lungs, or other organs confirmed by contrast-enhanced CT/MRI and whole-body bone scan within 4 weeks before enrollment
  • No previous esophageal resection surgery
  • No prior systemic chemotherapy
  • No prior thoracic radiation therapy over 10 Gy
  • No prior treatment with PD-1/PD-L1 immune checkpoint inhibitors
Not Eligible

You will not qualify if you...

  • Life expectancy less than 6 months (ECOG score 4 or Palliative Performance Scale 30% or less)
  • Legally incapacitated individuals without legal guardians
  • Active psychotic disorders such as schizophrenia or bipolar disorder
  • Dementia with MMSE score less than 24
  • Other exclusions determined by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 9 locations

1

Gansu Wuwei Cancer Hospital

Wuwei, Gansu, China

Actively Recruiting

2

Cancer Hospital Affiliated to Shantou University Medical College

Shantou, Guangdong, China

Not Yet Recruiting

3

Zhaoqing Gaoyao District People's Hospital

Zhaoqing, Guangdong, China

Actively Recruiting

4

Henan Cancer Hospital

Zhengzhou, Henan, China

Actively Recruiting

5

Tangdu Hospital

Xi'an, Shaanxi, China

Not Yet Recruiting

6

Xijing Hospital

Xi'an, Shaanxi, China

Actively Recruiting

7

The First Affiliated Hospital of Yan'an University

Yan’an, Shaanxi, China

Not Yet Recruiting

8

The First Affiliated Hospital of Shanxi Medical University

Taiyuan, Shanxi, China

Not Yet Recruiting

9

General Hospital of Western Theater Command, People's Liberation Army (PLA)

Chengdu, Sichuan, China

Actively Recruiting

Loading map...

Research Team

Z

Zhongyang Zhang

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here